by Jim Thompson | Mar 2, 2011 | CROI 2011 |
David E. Martin, PharmD, Senior Vice President, drug development/regulatory affairs, Tobira Therapeutics, Manalapan, NJ David discusses Tobira’s new CCR5/CCR2 receptor antagonist, currently in phase 2b. He covers past and current work and special benefits to...
by Jim Thompson | Mar 1, 2011 | CROI 2011 |
Dana Van Gorder and Judy Auerbach discuss the use of antiretrovirals in AIDS transmission prevention, pre-exposure prophylaxis (PrEP), and community viral load. To download an audio mp3 file, right-click here and choose...
by Jim Thompson | Mar 1, 2011 | CROI 2011 |
Franco Lori, MD, President and CEO, ViroStatics, Aleghero, Italy Dr. Lori describes his work and overviews other work at the CROI on immune hyperactivation that remains even when the viral load is controlled by the anti-HIV treatments. He describes the Virostatic...
by Jim Thompson | Feb 28, 2011 | CROI 2011 |
John James, AIDSNEWS.org, Philadelphia, PA John provides several new concepts and perspectives of the future of the way in which conferences may be operated. He covers the prospect of on-line media in which people can communicate better, less costly, more timely and...
by Jim Thompson | Feb 28, 2011 | CROI 2011 |
Nathaniel R. Landau, PhD, Professor, Department of Microbiology, New York University, New York City, NY Dr. Landau presented to the young investigator meeting, an overview of the work to be presented at the CROI in the field of Virology. Here he discusses the...
